Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome.

The study from 2008 examined the impact of metformin and rosiglitazone on glucose transporter 4 (GLUT4) mRNA expression in 35 women with polycystic ovary syndrome (PCOS), with 33 completing the trial. After 6 months of treatment, both drugs significantly increased GLUT4 mRNA expression in adipose tissue, with rosiglitazone showing a more pronounced effect. Improvements were also seen in insulin resistance, as indicated by the Homeostasis Model Assessment (HOMAIR) score, menstrual bleeding frequency, and serum total testosterone levels. The study concluded that both metformin and rosiglitazone enhance clinical, hormonal, and metabolic parameters in PCOS patients, with neither drug proving superior. Further research was suggested to explore the mechanisms of these treatments and their efficacy in different patient subgroups.